Cedar Mountain Advisors’s Myriad Genetics MYGN Stock Holding History

Cedar Mountain Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16	Closed	-$98	–	1183
2025 Q4	$98	Sell	16 -16	-50%	-$116	﹤0.01%	710
2025 Q3	$231	Buy	+32	New	+$190	﹤0.01%	645

Other funds holding MYGN

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Cedar Mountain Advisors's MYGN Position: Q1 2026 in Review

Cedar Mountain Advisors sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 16 shares — an estimated $98 sold.

Cedar Mountain Advisors first reported a position in MYGN in Q3 2025 and held it in 2 quarters. The position peaked at $231 in Q3 2025. 203 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

Cedar Mountain Advisors reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
Cedar Mountain Advisors sold 16 Myriad Genetics shares in Q1 2026, an estimated $98.
Cedar Mountain Advisors first reported a position in Myriad Genetics in Q3 2025 and held it in 2 quarters.
Cedar Mountain Advisors's Myriad Genetics position peaked at $231 in Q3 2025.
203 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Cedar Mountain Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.